Who is sponsoring NCT04115397?

NCT04115397 is sponsored by Karolinska Institutet.

What drugs are being tested in NCT04115397?

Interventions in NCT04115397: Zoledronic Acid, Placebo.

What condition does NCT04115397 study?

NCT04115397 studies Seropositive Muskuloskeletal Complaints.

Is NCT04115397 still recruiting?

NCT04115397 is currently status unknown. Last updated 3 October 2019.

Last reviewed 2019-10-03 · How we verify

NCT04115397: PREVENT RA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Towards Efficient Prediction and Prevention of Rheumatoid Arthritis

Status unknown Phase 4 Last updated 3 October 2019

What this trial tests

Phase 4 trial testing Zoledronic Acid in Seropositive Muskuloskeletal Complaints in 80 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
1 December 2021

1 December 2022

Quick facts

Lead sponsor	Karolinska Institutet
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	80
Start date	1 January 2020
Primary completion	1 December 2021
Estimated completion	1 December 2022

Drugs / interventions tested

Zoledronic Acid (ZOLEDRONIC ACID) — full drug profile →
Placebo

Conditions studied

Seropositive Muskuloskeletal Complaints — all drugs for Seropositive Muskuloskeletal Complaints →

Sponsor

Karolinska Institutet

Who can join

18 and older, any sex, with Seropositive Muskuloskeletal Complaints. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

VAS pain
Time frame: 3 months
PAin on a visual analogue scale

Sponsor's own description

Seropositive Rheumatoid arthritis (RA) is characterized by autoantibodies that develop prior to clinical onset, allowing identification of individuals at risk for disease development. In a unique program in Stockholm, seropositive individuals presenting with musculoskeletal complains are currently identified and followed-up in a dedicated outpatient clinical program. Despite significant disease burden and increased sick leave among these individuals, we lack today any therapeutic and preventive measures. We aim to (1). establish a nation-wide health program, (2). develop an algorithm for disease risk estimation and (3). test a novel strategy to delay and/or prevent disease onset in seropositive at risk individuals with musculoskeletal complains. We will perform a multicentre randomised study to treat autoantibody-positive individuals at risk for developing RA presenting with pain (Population), by repurposing of bisphosphonates (Intervention) as compared to placebo (Control) to treat pain (primary Outcome) and delay/prevent RA development during 1-year follow-up (secondary Outcome)

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

An up-to-date overview of computational polypharmacology in modern drug discovery.
Chaudhari R, Fong LW, Tan Z, Huang B, et al · · 2020 · cited 46× · PMID 32452701 · DOI 10.1080/17460441.2020.1767063

Verify or expand the search:

Other trials of Zoledronic Acid

Trials testing the same drug.

NCT05666310 — Muscle Impact of Treating Osteoporosis · Phase 4 · active not recruiting
NCT04597931 — Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density · Phase 4 · unknown
NCT04736693 — Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data · completed
NCT04087096 — Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery · Phase 4 · completed
NCT04303026 — The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip · Phase 3 · unknown

Other Karolinska Institutet trials

Trials by the same sponsor.

NCT06359262 — Evaluating the Hope@School Prevention Program · NA · not yet recruiting
NCT07289490 — Bilateral vs Unilateral Inguinal Hernia Repairs With an Asymptomatic Inguinal Hernia in Bilateral Hernias · NA · not yet recruiting
NCT06894264 — Emotion Processing and Regulation in People With Intellectual Disability · NA · not yet recruiting
NCT07494266 — Safety of a Healthy Plant-based Diet With Higher Potassium Content, Compared to a Healthy Plant-based Diet With Limited · NA · not yet recruiting
NCT07442032 — Cardiovascular Phenotypes in Sepsis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04115397 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Karolinska Institutet
Last refreshed: 3 October 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04115397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing